Skip to results
Modify your search
NARROW
1-20 of 21
Authors: Mirjam Renovanz
Journal Article
Sex-specific difference in treatment success/failure after vestibular schwannoma treatment
Neuro-Oncology Advances, Volume 7, Issue 1, January-December 2025, vdaf025, https://doi.org/10.1093/noajnl/vdaf025
Published: 29 January 2025
Journal Article
QOL-14. HEALTH-RELATED QUALITY OF LIFE AND COGNITIVE FUNCTIONING IN SURVIVORS OF OLIGODENDROGLIOMA: AN INTERNATIONAL CROSS-SECTIONAL INVESTIGATION
Neuro-Oncology, Volume 26, Issue Supplement_8, November 2024, Page viii265, https://doi.org/10.1093/neuonc/noae165.1049
Published: 11 November 2024
Journal Article
CTNI-85. FINAL RESULTS FROM N2M2/NOA-20
Neuro-Oncology, Volume 26, Issue Supplement_8, November 2024, Page viii117, https://doi.org/10.1093/neuonc/noae165.0451
Published: 11 November 2024
Journal Article
Preoperative growth dynamics of untreated glioblastoma: Description of an exponential growth type, correlating factors, and association with postoperative survival
Neuro-Oncology Advances, Volume 6, Issue 1, January-December 2024, vdae053, https://doi.org/10.1093/noajnl/vdae053
Published: 03 April 2024
Journal Article
App-based assessment of patient-reported outcomes in the Molecular Tumor Board in the Center for Personalized Medicine—(TRACE)
Neuro-Oncology Practice, Volume 11, Issue 3, June 2024, Pages 336–346, https://doi.org/10.1093/nop/npae002
Published: 20 January 2024
Journal Article
NCOG-32. THE SPECIFIC PSYCHOSOCIAL BURDEN OF CAREGIVERS OF ADULT NEURO-ONCOLOGICAL PATIENTS - A PROSPECTIVE STUDY
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v221, https://doi.org/10.1093/neuonc/noad179.0845
Published: 10 November 2023
Journal Article
CTNI-62. INTERIM DATA ON DUAL INHIBITION OF POST-RADIOGENIC ANGIO-VASCULOGENESIS BY OLAPTESED PEGOL (NOX-A12) AND BEVACIZUMAB IN GLIOBLASTOMA FROM THE FIRST EXPANSION ARM OF THE PHASE 1/2 GLORIA TRIAL
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Pages v90–v91, https://doi.org/10.1093/neuonc/noad179.0344
Published: 10 November 2023
Journal Article
CTIM-25. EO2401 PEPTIDE IMMUNOTHERAPY + NIVOLUMAB +/- BEVACIZUMAB IN FIRST RECURRENT GLIOBLASTOMA: THE PHASE 1/2 EOGBM1-18/ROSALIE STUDY (NCT04116658)
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Pages v67–v68, https://doi.org/10.1093/neuonc/noad179.0265
Published: 10 November 2023
Journal Article
NCOG-29. THE NEURO-ONCOLOGY MAGNITUDE OF CLINICAL BENEFIT SCALE (NEURO-MCBS) AS A COMPREHENSIVE AND CLINICALLY RELEVANT ASSESSMENT TOOL TO DETERMINE CLINICAL BENEFIT FROM TARGETED THERAPIES IN CNS TUMORS
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v220, https://doi.org/10.1093/neuonc/noad179.0842
Published: 10 November 2023
Journal Article
Towards more Diversity in Neuro-oncology Leadership—the DivINe Initiative
Neuro-Oncology, Volume 25, Issue 12, December 2023, Pages 2302–2304, https://doi.org/10.1093/neuonc/noad157
Published: 21 September 2023
Journal Article
Clinical outcome of biomarker-guided therapies in adult patients with tumors of the nervous system
Neuro-Oncology Advances, Volume 5, Issue 1, January-December 2023, vdad012, https://doi.org/10.1093/noajnl/vdad012
Published: 14 February 2023
Journal Article
CTNI-67. DUAL INHIBITION OF POST-RADIOGENIC ANGIO-VASCULOGENESIS BY OLAPTESED PEGOL (NOX-A12) AND BEVACIZUMAB IN GLIOBLASTOMA – INTERIM DATA FROM THE FIRST EXPANSION ARM OF THE GERMAN PHASE 1/2 GLORIA TRIAL
Neuro-Oncology, Volume 24, Issue Supplement_7, November 2022, Page vii88, https://doi.org/10.1093/neuonc/noac209.332
Published: 14 November 2022
Journal Article
CTNI-07. LOMUSTINE/TEMOZOLOMIDE CHEMOTHERAPY FOR NEWLY DIAGNOSED MGMT-METHYLATED IDHWT GLIOBLASTOMA ACCORDING TO CETEG/NOA-09: REAL-WORLD EXPERIENCE IN A MULTICENTER COHORT
Neuro-Oncology, Volume 24, Issue Supplement_7, November 2022, Page vii71, https://doi.org/10.1093/neuonc/noac209.274
Published: 14 November 2022
Journal Article
QOL-23. TOWARDS PATIENT-REPORTED OUTCOME ASSESSMENT IN THE MOLECULAR TUMOR BOARD – CANCER PATIENTS UNDER TARGETED THERAPY: APP-BASED ASSESSMENT OF PATIENT-REPORTED OUTCOMES (TRACE)
Neuro-Oncology, Volume 24, Issue Supplement_7, November 2022, Page vii246, https://doi.org/10.1093/neuonc/noac209.950
Published: 14 November 2022
Journal Article
CTIM-17. EO2401 THERAPEUTIC VACCINE FOR PATIENTS WITH RECURRENT GLIOBLASTOMA: PHASE 1/2 ROSALIE STUDY (NCT04116658)
Neuro-Oncology, Volume 24, Issue Supplement_7, November 2022, Page vii63, https://doi.org/10.1093/neuonc/noac209.249
Published: 14 November 2022
Journal Article
QOLP-27. NEURO-ONCOLOGICAL PATIENTS' AND CAREGIVERS' PSYCHOSOCIAL BURDEN DURING THE COVID-19 PANDEMIC – A PROSPECTIVE STUDY WITH QUALITATIVE CONTENT ANALYSIS
Neuro-Oncology, Volume 23, Issue Supplement_6, November 2021, Pages vi188–vi189, https://doi.org/10.1093/neuonc/noab196.747
Published: 12 November 2021
Journal Article
BIOM-38. THE PROGNOSTIC ROLE OF THE IMMUNOHISTOCHEMICAL MARKERS H3K27me3, SSTR1-5 AND BAP1 IN MENINGIOMA
Neuro-Oncology, Volume 23, Issue Supplement_6, November 2021, Page vi19, https://doi.org/10.1093/neuonc/noab196.069
Published: 12 November 2021
Journal Article
H3K27me3 loss indicates an increased risk of recurrence in the Tübingen meningioma cohort
Neuro-Oncology, Volume 23, Issue 8, August 2021, Pages 1273–1281, https://doi.org/10.1093/neuonc/noaa303
Published: 23 December 2020
Journal Article
Depatux-M and temozolomide in advanced high-grade glioma
Neuro-Oncology Advances, Volume 2, Issue 1, January-December 2020, vdaa063, https://doi.org/10.1093/noajnl/vdaa063
Published: 06 June 2020
Journal Article
Compliance with patient-reported outcome assessment in glioma patients: predictors for drop out
Neuro-Oncology Practice, Volume 5, Issue 2, June 2018, Pages 129–138, https://doi.org/10.1093/nop/npx026
Published: 31 October 2017
